5 Key Takeaways

• 1

  The Retina Innovation Summit panel discussed how evolving FDA guidance is reshaping retina drug development from clinical trials to approval.

• 2

  Panelists emphasized the increasing importance of regulatory strategy in the development of new ophthalmic therapies.

• 3

  The FDA's stance on sham controls in intravitreal injection studies has shifted, recognizing potential bias from patient awareness.

• 4

  Experts advised prioritizing high-quality data collection over larger datasets to answer clinically meaningful regulatory questions.

• 5

  Panelists agreed that early engagement with the FDA and careful evidence package construction are crucial for successful drug development.